Forums › Other Topics › Financial › Biolase First Quarter earnings release scheduled – April 27
- This topic is empty.
-
AuthorPosts
-
drnewittSpectatorBIOLASE Technology, Inc. (NASDAQ:BLTI) , a medical technology company that develops, manufactures and markets lasers and related products focused on improving dental procedures, announced that it intends to release its financial results for the first quarter ended March 31, 2004, prior to market open on Tuesday, April 27, 2004.
BIOLASE’s management will also host a conference call on Tuesday, April 27, 2004 at 11:30 a.m. EDT (8:30 a.m. PDT) to discuss its financial results.
To listen to the conference call live via the Internet, visit BIOLASE’s web site at [url=”http://www.biolase.com.”%5Dwww.biolase.com.%5B/url%5D Please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software. A replay of the call will be available on BIOLASE’s website for one year.
kellyjblodgettdmdSpectatorI wish I’d have puchased a lot more shares a year and a half ago when I bought my 1000 shares. I’ll be interested to see how they do this quarter. Thanks, Paul!
Kelly
AnonymousGuestHey Ray, what’s your take on what’s happening? Am I reading this correctly- profit was 轀k/~43k per Waterlase =~ 16 Waterlases?
lagunabbSpectatorHi Ron,
Total sales was 14.4 million and I believe 78% of that was from Waterlase sales. Assuming ASP of ฻k will get you around 261 units. My notes say that they mentioned 250 units during the conference call so that ฻K estimate of yours is pretty close. ASP is a 80/20 blend of north American and international sales and I believe the international realizations per unit can be quite different than NA ASP depending on exchange rates etc.
So they made 轀K/250 or about 񘣌 per machine and uncle sam and the Governator gets 񘔖 per machine. Other expenses are cost of goods (includes materials, assembly, packaging etc), R&D (has been running 10% of year-ago sales) , overhead and sales expenses take up the rest of pie. Sales expenses (marketing, training etc…) typically eats up a bigger proportion of the pie during the first quarter. Impressive sales. Management could have done a better job explaining the increase in overhead burden (general and adminstrative). Otherwise no complaints.
Forgot to add my disclosure:
I own Biolase stock(Edited by lagunabb at 8:54 am on May 3, 2004)
-
AuthorPosts